Adial Pharmaceuticals, Inc. (ADIL) on Monday said it has submitted its AD04 application for consideration under the U.S. Food and Drug Administration Commissioner's National Priority Voucher Pilot Program (CNPV).
The program allows companies to receive an expedited review of a drug application, including closer interaction with the FDA and a rolling review process.
Cary Claiborne, President and Chief Executive Officer of Adial, commented, "As we continue to advance the AD04 program and actively plan for the next phase of our clinical development efforts, we believe the Commissioners National Priority Voucher Pilot Program is an excellent strategic fit for AD04 and aligns well with our ongoing collaboration with the FDA."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.